Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to the BNF newsletter

Newsletter
December 2019

Welcome to the December BNF Newsletter.

• Two new drug monographs have been added to both BNF and BNF for Children in the last month: cannabidiol and lanadelumab. Three new drug monographs have been added to the BNF in the last month: caplacizumab, lamivudine with tenofovir disoproxil, and naldemedine. One new drug has been added to the BNF for Children in the last month: ceftaroline fosamil
• MHRA advice on adrenaline auto-injectors, ingenol mebutate gel (Picato®), nivolumab (Opdivo®), and ‘Prescribing in renal impairment’.

Kind regards,
BNF Team

Other topics:

Significant changes   |   Drug Safety Update   |   News

Significant changes

BNF BNF only

New monograph: Cablivi® [caplacizumab] for acquired thrombotic thrombocytopenic purpura (specialist use only)

New monograph: Lamivudine with tenofovir disoproxil for HIV-1 infection in combination with other antiretroviral drugs (initiated by a specialist)

New monograph: Rizmoic® [naldemedine] for opioid-induced constipation [previous treatment with a laxative]

Botulinum toxin type A for treating chronic sialorrhea [NICE guidance]

Idelalisib for treating refractory follicular lymphoma [NICE guidance]

Ingenol mebutate gel (Picato®): increased incidence of skin tumours seen in some clinical studies [MHRA/CHM advice]

Nivolumab (Opdivo®): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation [MHRA/CHM advice]

Prescribing in renal impairment: using the appropriate estimate of renal function to avoid the risk of adverse drug reactions [MHRA/CHM advice]

Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease [NICE guidance]

BNF BNF for Children Both BNF and BNF for Children

New monograph: Epidyolex® [cannabidiol] for seizures associated with Lennox-Gastaut syndrome [adjunctive treatment with clobazam] (specialist use only), and seizures associated with Dravet syndrome [adjunctive treatment with clobazam] (specialist use only)

New monograph: Takhzyro® [lanadelumab] for prevention of recurrent attacks of hereditary angioedema (initiated under specialist supervision)

Adrenaline auto-injectors: recent action taken to support safety [MHRA/CHM advice]

Bacillus Calmette-Guérin vaccine: updated guidance in line with Public Health England recommendations

Lanadelumab for preventing recurrent attacks of hereditary angioedema [NICE guidance]

Respiratory system infections, antibacterial therapy: updated guidance for community-acquired pneumonia

Respiratory system infections, antibacterial therapy: updated guidance for hospital-acquired pneumonia

BNF for Children BNF for Children Only

New monograph: Zinforo® [ceftaroline fosamil] for community-acquired pneumonia, complicated skin infections and complicated soft-tissue infections

 
Drug Safety Update
 

Drug Safety Update is a monthly newsletter from the MHRA and Commission on Human Medicine. Please follow this link to review the latest Drug Safety Update.

Carfilzomib (Kyprolis): risk of reactivation of hepatitis B virus

Yellow fever vaccine: stronger precautions in people with weakened immunity and in those aged 60 years or older

 
 

News

Please donate old copies of the BNF
The PharmAid Scheme is an initiative of the Commonwealth Pharmacists Association where recent versions of medicines information resources including the BNF are redistributed to low and middle income countries. You can make a difference in another commonwealth country by simply donating your old BNF copies to them.

For more information on this scheme see commonwealthpharmacy.org/what-we-do/pharmaid/. If you would like to donate your copy email: admin@commonwealthpharmacy.org.

 
 

How to purchase BNF

 
Print

Print
online

Online
Subscription

Subscription
eBook

eBook
 
 
 

Newsletter Feedback
Please let us know if there are any issues that you'd like us to address in our newsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.

SIGN UP

Copyright © 2019 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved.

Terms of use

Copyright © 2019 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved.

If you want to unsubscribe from emails from Pharmaceutical Press click here.

Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.